ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
104,729.71
1.06%
S&P 500
6,081.45
-0.08%
Dow Jones
44,249.47
0.21%
US Dollar vs Yen
156.263
-0.11%
Brent Oil
78.795
0.59%
Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. NLS Pharmaceutics Ltd (NLSP)

  7. NLS Pharmaceutics Ltd (NLSP) ニュース

NLSP

NLS Pharmaceutics (NLSP)

NLS Pharmaceutics Ltd
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:NLSP
日付受信時刻ニュースソース見出しコード企業名
2025/01/1623 : 32PR Newswire (US)Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLSNASDAQ:NLSPNLS Pharmaceutics Ltd
2025/01/0821 : 42PR Newswire (US)NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Share PriNASDAQ:NLSPNLS Pharmaceutics Ltd
2024/12/3021 : 30PR Newswire (US)NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed MergerNASDAQ:NLSPNLS Pharmaceutics Ltd
2024/12/0503 : 15PR Newswire (US)NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the MarketNASDAQ:NLSPNLS Pharmaceutics Ltd
2024/08/2805 : 01Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:NLSPNLS Pharmaceutics Ltd
2024/08/2705 : 40Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2024/08/1605 : 02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2024/08/1505 : 01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2024/07/3105 : 30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2024/07/1522 : 16Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:NLSPNLS Pharmaceutics Ltd
2024/03/1205 : 01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2024/02/2406 : 00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2024/01/1307 : 03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2023/12/3006 : 30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2023/12/2306 : 02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2023/12/0706 : 44Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2023/12/0506 : 45Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2023/12/0506 : 00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2023/12/0121 : 35Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2023/11/1706 : 05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2023/10/2605 : 30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2023/10/2522 : 02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2023/09/1405 : 03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2023/08/3106 : 25Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2023/07/2105 : 06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2023/07/0402 : 22Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2023/06/1421 : 38Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:NLSPNLS Pharmaceutics Ltd
2023/06/0921 : 30Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:NLSPNLS Pharmaceutics Ltd
2023/05/0821 : 31Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:NLSPNLS Pharmaceutics Ltd
2023/05/0605 : 37Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:NLSPNLS Pharmaceutics Ltd
 Showing the most relevant articles for your search:NASDAQ:NLSP

最近閲覧した銘柄

AMEX
XLE
Energy Select Sector SPDR
NYSE
CVX
Chevron
CCOM
US500
US 500
NYSE
MCD
McDonalds
CCOM
US30
US 30
NASDAQ
MSFT
Microsoft
FX
USDJPY
US Dollar vs Yen
FX
USDEUR
US Dollar vs Euro
NYSE
XOM
Exxon Mobil
NYSE
JPM
JP Morgan Chase
AMEX
XLF
Financial Select Sector
SPI
SP500
S&P 500
NYSE
BAC
Bank of America
USOTC
BNPQY
BNP Paribas (QX)
NASDAQ
GOOGL
Alphabet
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有